Objective To evaluate whether sedation with intramuscular butorphanol can interfere with different variables of the ocular examination in dogs. Animals Twenty-two beagles without ophthalmic abnormalities. Procedures Each dog was examined 20 min prior to and again just before administration of butorphanol to establish baseline data. The globe and nictitating membrane position was evaluated, and the following were recorded: menace response, dazzle reflex, corneal blink reflex, phenol red thread tear test (PRT), Schirmer tear test-1 (STT-1), pupil size (PS) measurement, and rebound tonometry. Then, butorphanol was injected intramuscularly at a dose of 0.2 mg/kg and these procedures were repeated 10, 20, 30, and 45 min postadministration. A sedation score graded 0 to 3 was also established at these time points. Statistical analyses were performed on quantitative data using ANOVA. Results The sedative effect was not associated with any changes in globe and nictitating membrane position; did not affect the results of the menace response, dazzle reflex, and corneal blink reflex; and had no significant effect on PRT values. However, butorphanol administration was associated with a statistically significant decrease in STT-1 and PS values (P < 0.005), and a statistically significant increase in IOP (P < 0.05). All these variations remained in the range of normal values. Conclusions and Clinical Relevance Butorphanol administered intramuscularly at 0.2 mg/kg provided a degree of sedation allowing eye examination, but was found to interfere with STT-1, PS, and IOP values among the diagnostic tests studied. However, these values remained within normal limits.
INTRODUCTION
A thorough eye examination is essential to diagnose ocular conditions but can be difficult to perform with uncooperative dogs. Sedation may be used as an adjunct to manual restraint to facilitate handling of these patients and reduce anxiety associated with ophthalmic examination. 1, 2 It also lowers the risk of injury to both the owner and practitioner 2 and can minimize ocular pain when it is severe enough to preclude a complete eye examination. 3 Acepromazine maleate, diazepam, and ketamine hydrochloride used solely or combined, and the tiletamine hydrochloride/zolazepam hydrochloride fixed combination are usually recommended for sedating ophthalmic canine patients. 4 Selection of a suitable protocol must consider extent and duration of the ophthalmic examination, as well as potential effects on animal health and ocular variables important in the diagnosis of ocular disease. 1, 5, 6 Inward rotation of the globe, nictitans protrusion, and changes in pupillary light reflexes, pupil size (PS), tear production, and intraocular pressure (IOP) are known side effects of chemical restraint which can hamper canine eye examination, and alter results of some ophthalmic diagnostic procedures.
Butorphanol has a pharmacological profile exemplary of the agonist-antagonist opioids with multiple actions through the opioid receptor system that are probably mu, delta, and kappa-mediated. 9, 10 It is mainly used as a preoperative or postoperative analgesic, 11, 12 but has also been recommended for sedating fractious canine patients with eye disease to facilitate ophthalmic examination. 4 As a paucity of data exists on its potential ocular effects in dogs, 2, 13 the present investigation was undertaken to evaluate butorphanol effects on various parameters pertinent to ophthalmic examination, in order to learn whether this opioid could represent an alternative to other sedative drugs for chemical restraint of canine ophthalmic patients.
MATERIALS A ND ME THODS
Twenty-two university-owned research beagles of both sexes (11 males and 11 females), aged 2 to 8 years (median: 4 years), and weighing 9-14 kg were selected for the study. The dogs were housed in approved facilities maintained at constant temperature (20 AE 2°C) and humidity (50 AE 10%), for at least 3 months prior to the study. Food was withheld for 12 h before the initiation of the experiments. Only healthy laboratory beagles with no ocular disease were included in the study. Each candidate dog underwent an ophthalmic examination that included slit-lamp biomicroscopy (Kowa SL-15L, Kowa Optimed Deutschland GMBH), rebound tonometry (Tonovet, Icare, Finland), binocular indirect ophthalmoscopy (Omegaâ500, Heine, Germany), and Schirmer tear test-1 (STT-1). All procedures were conducted according to the rules set forth in the ARVO resolution and European Community Council directive 86/609/EEC on animal experimentation.
Butorphanol sedation was evaluated, and its potential effects on ophthalmic examination were assessed using subjective (observed) and objective (measured) data, recorded from one eye of each dog randomly chosen via coin toss prior to the start of the study. The subjective parameters included observation of the globe and nictitating membrane positions, as well as evaluation of the menace response, dazzle reflex, and corneal blink reflex. The objective parameters included assessment of tear secretion using both phenol red thread tear test (PRT) and STT-1, intraocular pressure (IOP), and pupil size (PS). All parameters were initially evaluated 20 minutes prior to (T -20 ), and immediately prior to (T 0 ) administration of butorphanol to establish baseline presedation data. At T 0 , the dogs were given a dose of 0.2 mg/kg butorphanol tartrate (Dolorex, 10 mg/ml, Intervet International BV, Boxmeer, Netherlands) intramuscularly injected in the right lumbar muscles with a 25-gauge needle attached to a 1-ml syringe. Following butorphanol administration, the clinical variables mentioned above were evaluated at 10, 20, 30, and 45 min (T 10, T 20, T 30, and T 45 ). For each of these assessment times (T 10 through T 45 ), the degree of sedation was estimated using a 0-3 scoring system detailed in Table 1 and adapted from previous studies on the sedative effects of medetomidine, butorphanol, ketamine, and alfaxalone administered alone and in various combinations to healthy dogs. [14] [15] [16] At each time point following butorphanol administration, sedation was evaluated prior to the clinical variables to minimize the bias induced by the manipulation of the dog. 15 To mimic clinical practice, the ophthalmic tests were performed in the following order: observation of the globe and nictitating membrane positions, evaluation of the menace response, dazzle reflex, and corneal blink reflex, and then measurement of PRT, STT-1, IOP, and PS values. For assessment of the potential changes in globe and nictitating membrane position, pictures of the tested eyes were taken at each time point by one experimenter (JYD) using the same camera, and same camera settings to acquire all photographs. Pictures were blind coded and subjectively analyzed by another investigator (AR) after completion of the study. Menace response and dazzle reflex were performed according to standard rules, 8 and the corneal blink reflex was elicited by a brief puff of air delivered to the cornea through a 25-gauge needle hub attached to a 10-ml silicone bulb syringe held to the lateral side of the eye to avoid false-positive blink reflex from the menace response. 17 The menace response, dazzle reflex, and corneal blink reflex were noted as present or absent. For tear production assessment, the PRT readings (TV Test, Laboratoire TVM, Lempdes, France) were performed before those of STT-1 to decrease the bias produced by the Schirmer strip (Schirmer tear test, Merck Animal Health, Kenilworth, NJ, USA) on the tear lake volume. Intraocular pressure was measured using rebound tonometry with the dogs in either a sitting position or in sternal recumbency to avoid a possible influence of body position on IOP readings. 18 Resting PS measurements were made by use of a Jameson caliper (Lawton, Tubbingen, Germany) placed adjacent to the cornea, under the light conditions of the examination room corresponding to an artificial illumination ranging from 48 to 51 cd/m 2 (photometer S371R Optical Power Meter, Graseby Table 1 . Scoring system for evaluation of sedation induced by intramuscular administration of butorphanol at 0.2 mg/kg in the 22 dogs of the current study
No discernable effect of sedation 1
Mild sedation-signs of sedation but remains standing or sitting; appears calm; aware of the surrounding environment and reactive to verbal stimulation 2
Moderate sedation-appears sleepy but remains sitting or assumes sternal recumbency; no reaction to verbal stimulation but can be aroused with physical examination 3
Heavy sedation-inactive; assumes lateral recumbency; difficult to be aroused with physical examination Optronics, Orlando, FL, USA). 19 All data were recorded by one investigator (JYD) to minimize the variability of repeated measurements over time. At completion of all measurements, the eyes were examined by slit-lamp biomicroscopy without fluorescein to detect whether corneal surface changes had been induced by the procedure.
All measured data were expressed as mean (AESD) values. Changes of PRT, STT-1, PS, and IOP values over time were analyzed by use of a one-way ANOVA for repeated measures, followed by a Tukey's multiple comparison test to detect the differences between the mean baseline values, and those of the post-treatment time points. 20 Values of P < 0.05 were considered significant.
RE SUL TS
Following intramuscular administration of 0.2 mg/kg butorphanol, clinical signs of sedation developed in 21 of the 22 dogs. Mild sedation (score of 1) became clinically evident 10 (T 10 ) or 20 (T 20 ) minutes postinjection, in 16 and 5 of these animals, respectively. In 19 dogs, mild sedation was maintained until the end of the study period (T 45 ), while in 2 dogs, the mild sedation observed at T 10 turned into a moderate one (score of 2) from T 20 to T 45 . Dogs' cooperation for ophthalmic examination was noticeably improved as soon as clinical signs of sedation became apparent. Among the 22 dogs, data were recorded from 9 left and 13 right eyes, respectively. For all these eyes, the pupil remained centrally positioned, and the nictitating membrane never protruded following butorphanol administration. Normal menace response, dazzle reflex, and corneal blink reflex were observed throughout the study period. As the mean PRT, STT-1, PS, and IOP values were not statistically different (P > 0.05) between T -20 and T 0 , the data for each variable were pooled to obtain a mean value at baseline to compare with the postbutorphanol values. For the tested eyes, mean PRT and STT-1 values at baseline were 23.3 AE 5.6 mm/15 s and 19.7 AE 3.5 mm/min, respectively. No significant changes (P > 0.05) over time were observed for PRT values, while all postsedation STT-1 values were significantly lower (P < 0.05) than the baseline one (Fig. 1) . The largest change from baseline (~40%) was observed at T 45 with a mean STT-1 value of 12.4 AE 6.5 mm/min. In the tested eyes, the mean PS of 4.6 AE 1.0 mm at baseline was significantly reduced (P < 0.05) at each assessment time following butorphanol administration. The largest decrease in PS was noted at T 45 with a mean value of 3.2 AE 0.9 mm, representing a reduction of about 35% compared to baseline. The mean baseline IOP of 15.4 AE 2.5 mm Hg significantly increased (P < 0.05) from 10 to 45 min following butorphanol administration (Fig. 1) , with the maximal mean value of 18.1 AE 2.7 mm Hg observed at T 45 . Although this represented a maximal change of about 20% compared to baseline, all IOP measurements after butorphanol administration were within the normal range, with 22 mm Hg measured as the highest value. No signs of ocular discomfort (i.e., blepharospasm, epiphora) were clinically apparent in any of the tested eyes throughout the observation period, and no corneal changes were detected by slit-lamp examination at completion of the measurements, although fluorescein staining was not performed. However, because of the decrease in STT-1 measurements, a lubricant gel (Ocry-gel, TVM, Lempdes, France) was applied to each of the subjects' eye to protect the cornea. 
DISCUSSION
Parenteral administration (intravenous, intramuscular, or subcutaneous) of butorphanol at a dose of 0.1 to 0.4 mg/kg exerts dose-related sedative effects with minimal cardiopulmonary depression. 21 Sedation results from the stimulation of the kappa opioid receptors of the central nervous system. 11, 22, 23 The veterinary literature indicates that the sedative effect of intravenous butorphanol is not clinically relevant at a dose of 0.1 mg/kg 15 and is associated with a ventral rotation of the eyeballs that can preclude ophthalmic examination at a dose of 0.4 mg/kg. 21 The authors used this knowledge and their combined experience to choose an in-between dose of 0.2 mg/kg of butorphanol for the current study. The studied dose was injected intramuscularly because this mode of administration is easier to use in uncooperative patients than the intravenous injection, and because intramuscular injection of 0.2 mg/kg butorphanol has been previously reported to be suitable for abdominal ultrasonography in dogs which also requires adequate sedation. 24 Although none of the dogs included in the study showed signs of aggression, all were excitable dogs in the company of human beings and their excitement was visibly reduced in 21 of them after treatment. In these dogs, a mild-to-moderate degree of sedation was apparent within 10 to 20 min after butorphanol administration, until the end of the observation period (T 45 ), and was not associated with any change in the position of the globe or the nictitating membrane. By comparison, downward rotation of the globe and protrusion of the nictitating membrane, associated with profound sedation, are observed when butorphanol 0.1 mg/kg is combined with medetomidine 10 lg/kg, 25 or when medetomidine 33 lg/kg is administered solely. 26 No discernable effects on the menace response, dazzle reflex, and corneal blink reflex were detected in the current study, suggesting that the tested dose did not significantly interfere with the neuroanatomic pathways involved in these neuro-ophthalmic tests. 17 In the current study, butorphanol administration did not significantly affect the PRT values over time, but significantly reduced the STT-1 measurements at all time points following drug administration (T 10 to T 45 ). This tear-lowering effect is in agreement with the previous results of Dodam et al. 2 and was recently supposed to be additive or synergistic with that of medetomidine. 27 The effects of systemic opioids on canine tear production are drug dependent and probably mediated by different opioid receptors. Butorphanol, a mu antagonist-kappa agonist opioid, may reduce tear production similarly to pethidine (meperidine) and fentanyl, which are considered to be mureceptor agonists, 28, 29 while morphine, which is also a mu opioid agonist, had no effect on STT-1 values measured 30 min after administration. 30 Our observation that PRT, which measures only basal lacrimation in dogs, 31, 32 did not change over time after butorphanol administration, while STT-1 values declined, suggested that this opioid may interfere with the reflex augmentation of tear production. This is in keeping with one of the hypotheses of Dodam et al. 2 and may be explained by a blockade of the sensory signals from the ocular surface. 33 Although normal corneal blink reflex was maintained in all dogs after butorphanol administration, we cannot exclude that some degree of corneal sensitivity loss was present in our dogs. This observation warrants further studies using objective aesthesiometry, to quantify whether or not corneal sensitivity is altered in dogs sedated with butorphanol, as suggested in a previous investigation. 27 If butorphanol did not significantly decrease corneal sensitivity, another potential target for its effect might be the trigeminal spinal nucleus that encodes sensory information from the cornea under the influence of endogenous opioids. [34] [35] [36] Studies at the cellular level would be needed to resolve such an issue. Although the decrease in STT-1 readings was statistically significant, it was not as marked as those reported in dogs after administration of pethidine, 28 fentanyl, 28 and butorphanol-medetomidine combination. 27 Based on this, and the observation that STT-1 values remained at physiological levels, the use of butorphanol might be a better choice than the aforementioned drugs for sedation of patients suspected of or affected with low tear production. The pupillary effects of exogenous opioids are species dependent and are believed to be mediated predominantly through central mechanisms, although some data suggest a possible effect on iris opioid receptors. 37 Administration of opioids by various routes induces miosis in humans, dogs, and rabbits, while mydriasis is observed in monkeys, cats, and mice. [38] [39] [40] In all dogs of the current study, a significant pupillary constriction was observed at every time point following drug administration (T 10 to T 45 ), compared to baseline. The reduction in pupil diameter observed in the butorphanol-treated dogs was anticipated given that it has been previously reported after intravenous administration of 0.4 mg/kg. 21 The miotic potency of butorphanol has been found to be 8 times that of morphine in the canine species and is manifested at doses between 0.03 and 0.25 mg/kg with no additional constriction above 0.25 mg/kg. 41 While morphine-induced miosis in dogs is supposed to result from a direct effect on the Edinger-Westphal nucleus affecting its parasympathetic output to the sphincter muscle of the iris, 38,42 the mechanism by which butorphanol induces reduction in pupil size is still unknown. The kappa opioid receptors have been hypothetized to be involved in the process of pupil constriction, 9, 11 and their site of action could be, in part, the central nervous system. 43 With the exception of ketamine, which induces mydriasis in dogs, 44 most commonly used sedative agents are assumed to cause miosis in domestic animals. 5, 40 This has been recently documented in dogs with medetomidine, 45 dexmedetomidine, 46 and diazepam. 44 As mydriasis is necessary for lens and fundus examination, it would be relevant to know whether sedation of ophthalmic canine patients with butorphanol may prevent or delay pupillary dilation, a side effect reported with morphine in dogs. 47 This question justifies further studies to evaluate the rapidity, and degree of mydriasis after topical application of tropicamide in dogs sedated with butorphanol.
In our dogs, IOP levels were increased significantly over predrug (control) values at all evaluated time points following butorphanol administration (T 10 to T 45 ). The magnitude of elevation ranged from 7% at T 10 (mean increase = +1.1 mm Hg) to 20% at T 45 (mean increase = +2.7 mm Hg), but IOP remained at physiological levels throughout the study period. This finding is contrary to previous observations showing that opioids in general lower IOP, whatever the route of administration and the species to which the opioid is given. [48] [49] [50] Early studies in humans and rabbits with the mu opioid agonists morphine and heroin given systemically demonstrate that their IOP-lowering effect is associated with an increase in aqueous outflow facility. 51 More recent investigations using topical bremazocine, a specific kappa opioid agonist, found a reduction in aqueous inflow in rabbits and monkeys. 43, 52 Apart from one anecdotal report in the dog, 13 no other information on the effect of butorphanol on IOP could be found in the current literature. Therefore, the mechanism underlying its action on canine IOP is unknown, but theoretically may rely on changes in extraocular muscle tone, aqueous humor dynamics, or choroidal blood volume. 48 A decrease in PaO 2 , reflecting small alterations in ventilation, has been documented in dogs after intravenous administration of butorphanol at a dose of 0.1 or 0.4 mg/kg. 21 As this blood chemical change has been shown to increase choroidal blood volume and hence IOP, [53] [54] [55] this raises the question of its possible involvement in the IOP-increasing effect observed in our study. Further studies evaluating changes in choroidal blood flow after butorphanol administration are needed to lend support to this hypothesis. The magnitude of IOP elevation observed in our study is lower than that reported for ketamine 44 and is in the same range as that measured with diazepam using rebound tonometry. 44 Consequently, in ophthalmic patients with recognized or suspected glaucoma and those with suspicion of ruptured eye, butorphanol should be used with awareness of this potential effect or could be combined with a2-adrenoceptor agonists or acepromazine to inhibit the increase in IOP, as demonstrated in previous studies. 56, 57 The main limitation of the current study is the use of research dogs of only one breed, which raises the question of whether our results could be generalized to uncooperative subjects seen in practice, and particularly the very excitable and aggressive ones. Because it is known that the pharmacological effects of an opioid drug are not manifested similarly in every patient, 58 the sedative effect of butorphanol may differ significantly depending on the dog's breed, its character, and its level of excitement or aggressiveness. Individual variability to opioid administration has been documented in varying canine breeds 59 and may be illustrated by the fact that only 21 of 22 dogs showed a sedative effect after butorphanol administration, and that the degree of sedation varied between different individuals. In order to evaluate whether the results of the current study can be applied to the patient population seen in practice further investigation in a clinical practice setting would be necessary, using a study population large enough to include different canine breeds. Another objection could be raised that our study design included observed parameters (globe and nictitating membrane positions, menace response, dazzle reflex, and blink reflex) with subjective evaluation, and repeated measurements of various ophthalmic parameters (PRT, STT-1, PS measurement, and rebound tonometry) that might have influenced reliable assessment of each of them. First, to ensure optimal reliability of our data this study was performed by a trained veterinary ophthalmologist who used previously published procedures for evaluation of both the subjective and objective data. Second, it should be recognized that several investigators have already used serial measurements of STT-1 or IOP for studying the ocular effects of different sedative agents in dogs. 2, 30, 44, [60] [61] [62] [63] [64] In our study, PRT readings did not change over time, suggesting that the brief puff of air used to elicit the corneal blink reflex did not interfere with this parameter. Interaction of the puff of air on STT-1 readings cannot be eliminated, but such an interference is not reported in the literature. 17 Third, to address the concern of the potential effects of the repeated use of Schirmer test strips and rebound tonometry on corneal integrity, the authors performed slit-lamp examination of the tested eyes at completion of the ocular measurements. Although a fluorescein test was not performed, slit examination did not detect epithelial changes that could have influenced tear stimulation. This is in agreement with previous investigations in dogs, which did not report corneal side effects of serial STT-1 readings 30, 60, 63 and rebound tonometry measurements. 57, 65 In conclusion, the present study has shown that the sedative effect resulting from the intramuscular administration of 0.2 mg/kg of butorphanol was not associated with any change in the position of the globe and nictitating membrane, did not appear to influence the results of the basic tests of the neuro-ophthalmic examination, and did not modify basal tear secretion. The findings also suggest that the opioid can affect reflex tear production, IOP, and pupil size, which is in agreement with previous studies. Awareness of these parallel effects is important when considering the possible use of butorphanol as a sedative agent for ocular examination of a fractious dog.
